Quick Answer
Silexion Therapeutics Corp reported R&D Expense of $7.14 million for fiscal year 2025.
Silexion Therapeutics Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $7.14M | +22.8% |
| 2024 | $5.82M | +56.8% |
| 2023 | $3.71M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.16M | -32.9% | +111.9% |
| June 30, 2025 | $1.02M | +32.9% | +72.5% |
| March 31, 2025 | $590.0K | -38.6% | -81.7% |
| September 30, 2024 | $3.22M | +501.3% | +320.0% |
| June 30, 2024 | $766.0K | -38.0% | -20.3% |
| March 31, 2024 | $961.0K | — | +79.6% |
| September 30, 2023 | $535.0K | — | -56.7% |
| June 30, 2023 | $1.24M | — | — |
- Silexion Therapeutics Corp showed an increase of +22.8% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Silexion Therapeutics Corp’s r&d expense has grown by 92.6% (from $3.71 million to $7.14 million).
- The most recent figure is from Silexion Therapeutics Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: